Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Anticholinergic and antimuscarinic drug that acts in a similar fashion to atropin.
Prescribed for the treatment of symptoms related to hyperactive bladder.
Administered orally once a day.
We did not find published data regarding the excretion of this substance through breast milk at the time this last update was completed.
Due to its pharmacokinetic data (large distribution volume, moderately high molecular weight and high protein binding percentage: Astellas 2020, AEMPS 2018)
it is very unlikely for any significant amounts to pass into human milk, even though its long elimination half-life would facilitate it.
This drug is approved by the FDA for use by pediatric patients older than two years of age (Astellas 2020).
Expert authors regard this medication as probably safe to use during lactation. (Briggs 2017).
Anticholinergic drugs tend to decrease milk production therefore it is important to monitor milk production.
Be on the lookout for any signs of anticholinergic symptoms (dry mouth, constipation) on the breastfeeding child.
Until more published data regarding the interactions of this drug and breastfeeding is made available, it would be preferable the use of an alternative with a safer pharmacokinetic profile for lactation (with shorter elimination half-life and lower oral bioavailability), especially during the neonatal period or in the event of prematurity.